Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 11 January 2018


Restless Legs Syndrome
Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in adults.

Parkinson’s disease
Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ‘on-off’ fluctuations).

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

EPNS 2019 Congress Highlights

EPNS 2019 Congress Highlights

The team is creating daily reports from the 13th European Paediatric Neurology Society (EPNS) Congress, held in Athens, Greece from 17th to 21st September 2019, to bring you coverage of cutting-edge science and advances in clinical care across all fields of paediatric neurology. 

COMT inhibition in Parkinson's Disease

COMT inhibition in Parkinson's Disease

The COMT inhibition in Parkinson's Disease Learning Zone contains key information, expert opinion and interactive learning to highlight the benefit to patients of early levodopa treatment and diagnosis of the motor fluctuations which signal disease progression and prompt adjunctive treatment. Also deatiling key efficacy and safety data for the approved COMT inhibitors to help inform your treatment decisions. 

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000626
Orphan designation No
Date First Approved 15-02-2006
Type Medicinal product subject to medical prescription
Marketing authorisation holder UCB Pharma S.A.